- Home
- WYY vs RFL Comparison
WYY vs RFL Comparison
Compare WYY & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WYY | RFL |
|---|---|---|
| Founded | 1991 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Real Estate |
| Sector | Technology | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.2M | 61.1M |
| IPO Year | 2005 | 2017 |
Fundamental Metrics
Financial Performance| Metric | WYY | RFL |
|---|---|---|
| Price | $4.59 | $1.45 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $8.67 | N/A |
| AVG Volume (30 Days) | 44.0K | ★ 90.4K |
| Earning Date | 01-01-0001 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 54.35 | 28.28 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $142,571,749.00 | $917,000.00 |
| Revenue This Year | $5.20 | N/A |
| Revenue Next Year | $15.39 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 34.47 | ★ 43.96 |
| 52 Week Low | $2.19 | $1.12 |
| 52 Week High | $7.55 | $3.19 |
Technical Indicators
Market Signals| Indicator | WYY | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 38.91 | 69.73 |
| Support Level | $3.96 | $1.41 |
| Resistance Level | $7.39 | $1.64 |
| Average True Range (ATR) | 0.38 | 0.10 |
| MACD | 0.05 | 0.03 |
| Stochastic Oscillator | 46.11 | 67.14 |
Price Performance
Historical ComparisonAbout WYY WidePoint Corporation
WidePoint Corp is a provider of Technology Management as a Service (TMaaS) that consists of federally certified communications management, identity management, interactive bill presentment and analytics, and an Information Technology as a Service solution. Its solutions include Telecom Lifecycle Management, Digital billing communications solutions, and Mobile and Identity management. Geographically, the company generates a majority of its revenue from the United States and the rest from Europe.
About RFL Rafael Holdings Inc. Class B
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.